Anixa Biosciences Stock Price

-0.97 (-15.9%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 415,078
Bid Price 3.94
Ask Price 6.10
News -
Day High 6.15


52 Week Range


Day Low 4.95
Company Name Stock Ticker Symbol Market Type
Anixa Biosciences Inc ANIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.97 -15.9% 5.13 00:00:05
Open Price Low Price High Price Close Price Prev Close
6.15 4.95 6.15 5.13 6.10
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,360 415,078 $ 5.32 $ 2,210,290 - 2.30 - 6.2491
Last Trade Time Type Quantity Stock Price Currency
18:19:15 9 $ 4.94 USD


Draw Mode:

Anixa Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 154.68M 30.15M 28.70M $ 512.50k $ - -0.44 -7.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.34M 16.60%

more financials information »

Anixa Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ANIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.486.24914.355.91328,6220.6514.51%
1 Month4.156.24914.005.46119,6410.9823.61%
3 Months3.056.24912.774.5381,1732.0868.2%
6 Months2.676.24912.503.8583,9392.4692.13%
1 Year4.856.24912.303.74102,8010.285.77%
3 Years4.348.091.333.74253,8590.7918.2%
5 Years4.488.091.333.82211,6350.6514.51%

Anixa Biosciences Description

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.

Your Recent History
Anixa Bios..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now